Linked Life Data

17702855

Source:http://linkedlifedata.com/resource/pubmed/id/17702855

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2007-9-21
pubmed:abstractText
Proprotein convertase subtilisin kexin type 9 (PCSK9) is gaining attention as a key regulator of serum LDL-cholesterol (LDLC). This novel serine protease causes the degradation of hepatic LDL receptors by an unknown mechanism. In humans, gain-of-function mutations in the PCSK9 gene cause a form of familial hypercholesterolemia, whereas loss-of-function mutations result in significantly decreased LDLC and decreased cardiovascular risk. Relatively little is known about PCSK9 in human serum.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0009-9147
pubmed:author
pubmed:issnType
Print
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1814-9
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
pubmed:affiliation
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't